NCT01133522View on ClinicalTrials.gov

Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2010

Primary Completion Date

September 14, 2011

Study Completion Date

September 14, 2011

Conditions
Hyperlipidemia
Interventions
BIOLOGICAL

Evolocumab

Administered by subcutaneous injection

BIOLOGICAL

Placebo

Administered by subcutaneous injection

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01133522 - Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin | Biotech Hunter | Biotech Hunter